Hims & Hers Health (NYSE:HIMS) Announces Quarterly Earnings Results

Hims & Hers Health (NYSE:HIMS) released its quarterly earnings results on Monday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32), FiscalAI reports. The firm had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.89 million. Hims & Hers Health had a negative return on equity of 5.89% and a negative net margin of 5.51%.Hims & Hers Health’s revenue for the quarter was up 38.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.17 earnings per share.

Here are the key takeaways from Hims & Hers Health’s conference call:

• Revenue and subscriber growth accelerated. Q2 revenue rose nearly 40% year over year to more than $753 million, with 300,000 net new subscribers bringing the total to nearly 3 million; management raised full-year 2026 revenue guidance to $3.1 billion–$3.3 billion.
• The company reported early benefits from its AI-native care platform, including three times more customer messaging, an approximately 50% reduction in non-clinical support tasks, and lower cancellation rates in pilot cohorts. Management expects AI investments to pay back within 12–18 months and support improved retention and cost efficiency.
• International expansion is becoming a major growth driver following the Eucalyptus acquisition. International revenue increased more than 17-fold year over year to $131 million, and the company expects international revenue of at least $600 million in 2026 while expanding U.S. specialties such as testosterone, sexual health, and dermatology overseas.
• New growth opportunities include injectable and oral testosterone before year-end and peptide-related wellness offerings, subject to regulatory developments. The company expects to launch already permitted offerings such as sermorelin, glutathione, and NAD+ by year-end, while awaiting final FDA rulemaking for additional peptides.
• Profitability and cash flow faced near-term pressure from the business mix and one-time costs. Adjusted gross margin fell to 64% as branded weight-loss products and international revenue grew, Q2 free cash flow was negative $68 million, and the company incurred approximately $81 million in acquisition, restructuring, and FTC-related legal costs; management also said international operations may remain near breakeven as it invests for scale.

Hims & Hers Health Stock Performance

NYSE HIMS traded down $0.84 during trading hours on Wednesday, reaching $29.67. The stock had a trading volume of 2,419,532 shares, compared to its average volume of 26,648,326. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $65.30. The stock has a fifty day moving average of $32.01 and a 200 day moving average of $26.09. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The stock has a market cap of $6.87 billion, a P/E ratio of -46.93, a price-to-earnings-growth ratio of 89.41 and a beta of 2.40.

Wall Street Analysts Forecast Growth

HIMS has been the topic of several research analyst reports. Jefferies Financial Group set a $24.50 target price on Hims & Hers Health in a research note on Tuesday, May 12th. Morgan Stanley raised their price target on Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a report on Tuesday. Needham & Company LLC upped their price objective on shares of Hims & Hers Health from $35.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday. Truist Financial increased their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research note on Tuesday. Four research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and a consensus target price of $32.43.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Second-quarter revenue rose 38.2% year over year to approximately $753.2 million, exceeding analysts’ expectations of about $698.9 million. Subscriber growth and expanding personalized healthcare offerings supported the performance. Hims & Hers raises annual forecast revenue on strong subscriber growth
• Positive Sentiment: Management raised its 2026 revenue forecast to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion and issued third-quarter revenue guidance of $880 million-$900 million, above consensus. AI-driven engagement, specialty care and international expansion were cited as growth drivers. HIMS Q2 Earnings Call Focuses on AI and Global Expansion
• Positive Sentiment: Needham raised its price target to $42 and maintained a Buy rating, arguing that current investments could support longer-term incremental growth. Needham price-target update
• Neutral Sentiment: Analyst views were mixed: Bank of America raised its target to $32 while retaining a Neutral rating, whereas Citigroup cut its target to $33 and also remained Neutral. These targets suggest limited near-term upside at the referenced share price. Analyst price-target changes
• Negative Sentiment: HIMS reported a quarterly loss of $0.37 per share, far worse than the approximately $0.05 loss analysts expected. The shift toward branded GLP-1 weight-loss drugs, restructuring costs and international expansion increased expenses and pressured gross margins. Hims & Hers shares slide as costly weight-loss push squeezes margins
• Negative Sentiment: Investors remain concerned that the revenue guidance increase does not resolve margin compression, negative free cash flow and a stagnant adjusted EBITDA outlook. This makes the company’s aggressive growth strategy less attractive from a profitability perspective. The Guidance Raise Doesn’t Fix the Margin Problem
• Negative Sentiment: The FTC’s continuing investigation and newly filed consumer class-action litigation add regulatory, legal and reputational risks. Separate law-firm investigations into potential securities-law violations may further weigh on sentiment. FTC investigation and consumer class action

Insider Activity at Hims & Hers Health

In other news, insider Patrick Harrison Carroll sold 23,726 shares of the company’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total value of $830,410.00. Following the sale, the insider directly owned 181,861 shares of the company’s stock, valued at $6,365,135. This represents a 11.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David B. Wells acquired 48,400 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was acquired at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the purchase, the director directly owned 224,417 shares of the company’s stock, valued at approximately $5,437,623.91. This trade represents a 27.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 83,126 shares of company stock worth $2,711,339 in the last ninety days. 11.76% of the stock is owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently added to or reduced their stakes in the business. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health during the 3rd quarter valued at about $28,000. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the first quarter worth about $30,000. Greenline Wealth Management LLC acquired a new stake in Hims & Hers Health during the fourth quarter worth about $36,000. DV Equities LLC acquired a new stake in Hims & Hers Health during the fourth quarter worth about $46,000. Finally, EverSource Wealth Advisors LLC raised its position in Hims & Hers Health by 273.7% during the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after acquiring an additional 687 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.